Do analysts rate AADI or CRVO?

CervoMed has a consensus target price of $22.60, suggesting a potential upside of 682.01%. Given CervoMed's stronger consensus rating and higher possible upside, analysts plainly believe CervoMed is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CervoMed 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Is AADI or CRVO more profitable?

Aadi Bioscience has a net margin of -246.06% compared to CervoMed's net margin of -672.80%. Aadi Bioscience's return on equity of -71.87% beat CervoMed's return on equity. Company Net Margins Return on Equity Return on Assets Aadi Bioscience -246.06% -71.87% -57.28% CervoMed -672.80% -136.08% -112.62%

Does the media refer more to CGTX or CRVO?

In the previous week, CervoMed had 1 more articles in the media than Cognition Therapeutics. MarketBeat recorded 4 mentions for CervoMed and 3 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.83 beat CervoMed's score of 0.75 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CervoMed 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRVO or ALDX?

In the previous week, Aldeyra Therapeutics had 4 more articles in the media than CervoMed. MarketBeat recorded 8 mentions for Aldeyra Therapeutics and 4 mentions for CervoMed. Aldeyra Therapeutics' average media sentiment score of 0.85 beat CervoMed's score of 0.75 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CervoMed 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aldeyra Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CRVO or PEPG more profitable?

PepGen has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. PepGen's return on equity of -59.89% beat CervoMed's return on equity. Company Net Margins Return on Equity Return on Assets CervoMed -672.80% -136.08% -112.62% PepGen N/A -59.89% -49.62%

Does the media prefer CRVO or PEPG?

In the previous week, CervoMed had 1 more articles in the media than PepGen. MarketBeat recorded 4 mentions for CervoMed and 3 mentions for PepGen. CervoMed's average media sentiment score of 0.75 beat PepGen's score of 0.63 indicating that CervoMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CervoMed 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PepGen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CRVO or IZTC?

CervoMed currently has a consensus price target of $22.60, indicating a potential upside of 682.01%. Given CervoMed's stronger consensus rating and higher probable upside, equities analysts clearly believe CervoMed is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CervoMed 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, CRVO or IZTC?

Invizyne Technologies has lower revenue, but higher earnings than CervoMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CervoMed $4.01M 6.67 -$26.97M -$3.28 N/A Invizyne Technologies N/A N/A N/A N/A N/A

CervoMed (CRVO) Competitors

$2.89 -0.02 (-0.69%)

Closing price 04:00 PM Eastern

Extended Trading

$2.89 0.00 (0.00%)

As of 07:31 PM Eastern

Compare

CRVO vs. AADI, CGTX, ALDX, PEPG, and IZTC

Should you buy CervoMed stock or one of its competitors? MarketBeat compares CervoMed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CervoMed include Aadi Bioscience (AADI), Cognition Therapeutics (CGTX), Aldeyra Therapeutics (ALDX), PepGen (PEPG), and Invizyne Technologies (IZTC). These companies are all part of the "pharmaceutical products" industry.

How does CervoMed compare to Aadi Bioscience?

Aadi Bioscience (NASDAQ:AADI) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

In the previous week, CervoMed had 4 more articles in the media than Aadi Bioscience. MarketBeat recorded 4 mentions for CervoMed and 0 mentions for Aadi Bioscience. CervoMed's average media sentiment score of 0.75 beat Aadi Bioscience's score of 0.00 indicating that CervoMed is being referred to more favorably in the news media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
CervoMed	Positive

Aadi Bioscience has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, CervoMed has a beta of -0.68, indicating that its stock price is 168% less volatile than the broader market.

CervoMed has a consensus target price of $22.60, suggesting a potential upside of 682.01%. Given CervoMed's stronger consensus rating and higher possible upside, analysts plainly believe CervoMed is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

CervoMed has lower revenue, but higher earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	3.96	-$65.76M	-$2.35	N/A
CervoMed	$4.01M	6.67	-$26.97M	-$3.28	N/A

Aadi Bioscience has a net margin of -246.06% compared to CervoMed's net margin of -672.80%. Aadi Bioscience's return on equity of -71.87% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
CervoMed	-672.80%	-136.08%	-112.62%

52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 25.2% of CervoMed shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by insiders. Comparatively, 35.4% of CervoMed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Aadi Bioscience and CervoMed tied by winning 8 of the 16 factors compared between the two stocks.

How does CervoMed compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Cognition Therapeutics has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Cognition Therapeutics' return on equity of -72.68% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
CervoMed	-672.80%	-136.08%	-112.62%

Cognition Therapeutics has higher earnings, but lower revenue than CervoMed. Cognition Therapeutics is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
CervoMed	$4.01M	6.67	-$26.97M	-$3.28	N/A

Cognition Therapeutics has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, CervoMed has a beta of -0.68, suggesting that its share price is 168% less volatile than the broader market.

43.3% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 25.2% of CervoMed shares are owned by institutional investors. 11.1% of Cognition Therapeutics shares are owned by company insiders. Comparatively, 35.4% of CervoMed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, CervoMed had 1 more articles in the media than Cognition Therapeutics. MarketBeat recorded 4 mentions for CervoMed and 3 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.83 beat CervoMed's score of 0.75 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CervoMed	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cognition Therapeutics currently has a consensus price target of $3.33, indicating a potential upside of 189.86%. CervoMed has a consensus price target of $22.60, indicating a potential upside of 682.01%. Given CervoMed's stronger consensus rating and higher possible upside, analysts plainly believe CervoMed is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Cognition Therapeutics beats CervoMed on 8 of the 15 factors compared between the two stocks.

How does CervoMed compare to Aldeyra Therapeutics?

CervoMed (NASDAQ:CRVO) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

25.2% of CervoMed shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 35.4% of CervoMed shares are held by insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

CervoMed has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	6.67	-$26.97M	-$3.28	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A

CervoMed has a beta of -0.68, indicating that its share price is 168% less volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market.

Aldeyra Therapeutics has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Aldeyra Therapeutics' return on equity of -57.34% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-136.08%	-112.62%
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

CervoMed currently has a consensus price target of $22.60, suggesting a potential upside of 682.01%. Aldeyra Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 219.77%. Given CervoMed's stronger consensus rating and higher probable upside, analysts plainly believe CervoMed is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Aldeyra Therapeutics had 4 more articles in the media than CervoMed. MarketBeat recorded 8 mentions for Aldeyra Therapeutics and 4 mentions for CervoMed. Aldeyra Therapeutics' average media sentiment score of 0.85 beat CervoMed's score of 0.75 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CervoMed	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aldeyra Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aldeyra Therapeutics beats CervoMed on 8 of the 15 factors compared between the two stocks.

How does CervoMed compare to PepGen?

CervoMed (NASDAQ:CRVO) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

In the previous week, CervoMed had 1 more articles in the media than PepGen. MarketBeat recorded 4 mentions for CervoMed and 3 mentions for PepGen. CervoMed's average media sentiment score of 0.75 beat PepGen's score of 0.63 indicating that CervoMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CervoMed	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PepGen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CervoMed has a beta of -0.68, meaning that its share price is 168% less volatile than the broader market. Comparatively, PepGen has a beta of 1.93, meaning that its share price is 93% more volatile than the broader market.

PepGen has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. PepGen's return on equity of -59.89% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-136.08%	-112.62%
PepGen	N/A	-59.89%	-49.62%

CervoMed has higher revenue and earnings than PepGen. CervoMed is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	6.67	-$26.97M	-$3.28	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

25.2% of CervoMed shares are owned by institutional investors. Comparatively, 58.0% of PepGen shares are owned by institutional investors. 35.4% of CervoMed shares are owned by company insiders. Comparatively, 1.3% of PepGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CervoMed currently has a consensus target price of $22.60, indicating a potential upside of 682.01%. PepGen has a consensus target price of $11.60, indicating a potential upside of 740.58%. Given PepGen's stronger consensus rating and higher possible upside, analysts clearly believe PepGen is more favorable than CervoMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

PepGen beats CervoMed on 9 of the 15 factors compared between the two stocks.

How does CervoMed compare to Invizyne Technologies?

CervoMed (NASDAQ:CRVO) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

CervoMed currently has a consensus price target of $22.60, indicating a potential upside of 682.01%. Given CervoMed's stronger consensus rating and higher probable upside, equities analysts clearly believe CervoMed is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Invizyne Technologies has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Invizyne Technologies' return on equity of 0.00% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-136.08%	-112.62%
Invizyne Technologies	N/A	N/A	N/A

In the previous week, CervoMed had 4 more articles in the media than Invizyne Technologies. MarketBeat recorded 4 mentions for CervoMed and 0 mentions for Invizyne Technologies. CervoMed's average media sentiment score of 0.75 beat Invizyne Technologies' score of 0.00 indicating that CervoMed is being referred to more favorably in the media.

Company	Overall Sentiment
CervoMed	Positive
Invizyne Technologies	Neutral

Invizyne Technologies has lower revenue, but higher earnings than CervoMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	6.67	-$26.97M	-$3.28	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

25.2% of CervoMed shares are held by institutional investors. 35.4% of CervoMed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

CervoMed beats Invizyne Technologies on 8 of the 11 factors compared between the two stocks.

Get CervoMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRVO vs. The Competition

Export

Metric	CervoMed	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$26.76M	$3.31B	$6.48B	$11.95B
Dividend Yield	N/A	2.31%	2.67%	5.58%
P/E Ratio	-0.88	19.00	24.56	23.76
Price / Sales	6.67	304.93	531.16	116.35
Price / Cash	N/A	51.45	26.99	37.23
Price / Book	1.47	8.18	10.52	6.75
Net Income	-$26.97M	$23.83M	$3.56B	$337.35M
7 Day Performance	-3.67%	-2.82%	-1.11%	-2.54%
1 Month Performance	-26.84%	2.22%	1.28%	1.42%
1 Year Performance	-62.66%	37.70%	21.20%	24.71%

CervoMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRVO CervoMed	3.6899 of 5 stars	$2.89 -0.7%	$22.60 +682.0%	-61.8%	$26.76M	$4.01M	N/A	4	News Coverage
AADI Aadi Bioscience	N/A	$4.49 -4.9%	N/A	+121.9%	$110.89M	$25.07M	N/A	40
CGTX Cognition Therapeutics	3.9944 of 5 stars	$1.36 +8.5%	$3.33 +145.8%	+309.8%	$105.61M	N/A	N/A	20	Positive News Gap Up High Trading Volume
ALDX Aldeyra Therapeutics	3.5269 of 5 stars	$1.59 -4.5%	$5.50 +247.0%	-34.6%	$105.56M	N/A	N/A	10	Analyst Upgrade Gap Up
PEPG PepGen	2.3375 of 5 stars	$1.44 -2.4%	$11.60 +708.4%	-10.0%	$103.75M	N/A	N/A	30	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRVO) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CervoMed (CRVO) Competitors

CRVO vs. AADI, CGTX, ALDX, PEPG, and IZTC

How does CervoMed compare to Aadi Bioscience?

Summary

How does CervoMed compare to Cognition Therapeutics?

Summary

How does CervoMed compare to Aldeyra Therapeutics?

Summary

How does CervoMed compare to PepGen?

Summary

How does CervoMed compare to Invizyne Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVO vs. The Competition

CervoMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CervoMed (CRVO) Competitors

CRVO vs. AADI, CGTX, ALDX, PEPG, and IZTC

How does CervoMed compare to Aadi Bioscience?

Does the media favor AADI or CRVO?

Which has more risk and volatility, AADI or CRVO?

Do analysts rate AADI or CRVO?

Which has preferable valuation and earnings, AADI or CRVO?

Is AADI or CRVO more profitable?

Do insiders & institutionals believe in AADI or CRVO?

Summary

How does CervoMed compare to Cognition Therapeutics?

Is CGTX or CRVO more profitable?

Which has preferable earnings & valuation, CGTX or CRVO?

Which has more volatility and risk, CGTX or CRVO?

Do insiders & institutionals have more ownership in CGTX or CRVO?

Does the media refer more to CGTX or CRVO?

Do analysts rate CGTX or CRVO?

Summary

How does CervoMed compare to Aldeyra Therapeutics?

Do insiders and institutionals hold more shares of CRVO or ALDX?

Which has preferable valuation and earnings, CRVO or ALDX?

Which has more volatility & risk, CRVO or ALDX?

Is CRVO or ALDX more profitable?

Do analysts rate CRVO or ALDX?

Does the media favor CRVO or ALDX?

Summary

How does CervoMed compare to PepGen?

Does the media prefer CRVO or PEPG?

Which has more risk & volatility, CRVO or PEPG?

Is CRVO or PEPG more profitable?

Which has preferable earnings & valuation, CRVO or PEPG?

Do institutionals & insiders have more ownership in CRVO or PEPG?

Do analysts recommend CRVO or PEPG?

Summary

How does CervoMed compare to Invizyne Technologies?

Do analysts recommend CRVO or IZTC?

Is CRVO or IZTC more profitable?

Does the media prefer CRVO or IZTC?

Which has preferable earnings & valuation, CRVO or IZTC?

Do institutionals and insiders have more ownership in CRVO or IZTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVO vs. The Competition

CervoMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools